Literature DB >> 24255582

Effects of tyrosine kinase inhibitor E7080 and eNOS inhibitor L-NIO on colorectal cancer alone and in combination.

Ahmet Altun1, Tijen Kaya Temiz, Ezgi Balcı, Zübeyde Akın Polat, Mustafa Turan.   

Abstract

OBJECTIVE: To investigate the effects of E7080 and N (5)-(1-iminoethyl)-L-ornithine dihydrochloride (L-NIO) on colorectal cancer alone and in combination.
METHODS: HT29 colorectal cancer cell line from Sap Institute was used. Real-time cell analysis (xCELLigence system) was performed to determine the effects of E7080 and L-NIO on colorectal cell proliferation. While apoptosis was determined with Annexin V staining, and the effect of agents on angiogenesis was determined with chorioallantoic membrane (CAM) model.
RESULTS: We found that E7080 has a strong antiproliferative effect with an half maximum inhibition of concentration (IC50) value of 5.60×10(-8) mol/L. Also it has been observed that E7080 showed antiangiogenic and apoptotic effects on HT29 colorectal cancer cells. Antiangiogenic scores of E7080 were 1.2, 1.0 and 0.6 for 100, 10 and 1 nmol/L E7080 concentrations, respectively. Furthermore, apoptosis has been detected in 71% of HT29 colorectal cancer cells after administration of 100 nmol/L E7080 which may indicate strong apoptotic effect. Meanwhile administration of L-NIO alone did not show any effect, but the combination of E7080 with L-NIO increased the antiproliferative, antiangiogenic and apoptotic effects of E7080.
CONCLUSIONS: Results of this study indicate that E7080 may be a good choice in treatment of colorectal tumors. Furthermore the increased effects of E7080 when combined with L-NIO raise the possibility to use a lower dose of E7080 and therefore avoid/minimize the side effects observed with E7080.

Entities:  

Keywords:  E7080; N5-(1-iminoethyl)-L-ornithine dihydrochloride (L-NIO); colorectal cancer; tyrosine kinase (TK); xCELLigence system

Year:  2013        PMID: 24255582      PMCID: PMC3828440          DOI: 10.3978/j.issn.1000-9604.2013.10.10

Source DB:  PubMed          Journal:  Chin J Cancer Res        ISSN: 1000-9604            Impact factor:   5.087


  43 in total

1.  p53-mediated induction of Noxa and p53AIP1 requires NFkappaB.

Authors:  Jim O'Prey; Diane Crighton; Angel G Martin; Karen H Vousden; Howard O Fearnhead; Kevin M Ryan
Journal:  Cell Cycle       Date:  2010-03-07       Impact factor: 4.534

2.  A multi-institutional phase ii study of SU101, a platelet-derived growth factor receptor inhibitor, for patients with hormone-refractory prostate cancer.

Authors:  Y J Ko; E J Small; F Kabbinavar; A Chachoua; S Taneja; D Reese; A DePaoli; A Hannah; S P Balk; G J Bubley
Journal:  Clin Cancer Res       Date:  2001-04       Impact factor: 12.531

3.  Overexpression of osteopontin induces angiogenesis of endothelial progenitor cells via the avβ3/PI3K/AKT/eNOS/NO signaling pathway in glioma cells.

Authors:  Yingyi Wang; Wei Yan; Xiaoming Lu; Chunfa Qian; Junxia Zhang; Ping Li; Lei Shi; Peng Zhao; Zhen Fu; Peiyu Pu; Chunshen Kang; Tao Jiang; Ning Liu; Yongping You
Journal:  Eur J Cell Biol       Date:  2011-05-26       Impact factor: 4.492

4.  Transactivation of vascular endothelial growth factor (VEGF) receptor Flk-1/KDR is involved in sphingosine 1-phosphate-stimulated phosphorylation of Akt and endothelial nitric-oxide synthase (eNOS).

Authors:  Tatsuo Tanimoto; Zheng-Gen Jin; Bradford C Berk
Journal:  J Biol Chem       Date:  2002-09-10       Impact factor: 5.157

5.  LaPSvS1, a (1-->3)-beta-galactan sulfate and its effect on angiogenesis in vivo and in vitro.

Authors:  Jutta Bürgermeister; Dietrich H Paper; Horst Vogl; Robert J Linhardt; Gerhard Franz
Journal:  Carbohydr Res       Date:  2002-09-09       Impact factor: 2.104

6.  Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial.

Authors:  Mark G Kris; Ronald B Natale; Roy S Herbst; Thomas J Lynch; Diane Prager; Chandra P Belani; Joan H Schiller; Karen Kelly; Harris Spiridonidis; Alan Sandler; Kathy S Albain; David Cella; Michael K Wolf; Steven D Averbuch; Judith J Ochs; Andrea C Kay
Journal:  JAMA       Date:  2003-10-22       Impact factor: 56.272

Review 7.  Life history of eNOS: partners and pathways.

Authors:  David M Dudzinski; Thomas Michel
Journal:  Cardiovasc Res       Date:  2007-04-03       Impact factor: 10.787

Review 8.  Integration of novel agents in the treatment of colorectal cancer.

Authors:  Syma Iqbal; Heinz-Josef Lenz
Journal:  Cancer Chemother Pharmacol       Date:  2004-09       Impact factor: 3.333

Review 9.  Role of eNOS in neovascularization: NO for endothelial progenitor cells.

Authors:  Dan G Duda; Dai Fukumura; Rakesh K Jain
Journal:  Trends Mol Med       Date:  2004-04       Impact factor: 11.951

10.  E7080, a multi-targeted tyrosine kinase inhibitor suppresses tumor cell migration and invasion.

Authors:  Hilary Glen; Susan Mason; Hitesh Patel; Kenneth Macleod; Valerie G Brunton
Journal:  BMC Cancer       Date:  2011-07-22       Impact factor: 4.430

View more
  7 in total

Review 1.  Emerging enzymatic targets controlling angiogenesis in cancer: preclinical evidence and potential clinical applications.

Authors:  Biagio Ricciuti; Jennifer Foglietta; Rita Chiari; Amirhossein Sahebkar; Maciej Banach; Vanessa Bianconi; Matteo Pirro
Journal:  Med Oncol       Date:  2017-12-04       Impact factor: 3.064

2.  The anti-angiogenic potential of (±) gossypol in comparison to suramin.

Authors:  Gönül Ulus; A Tansu Koparal; Kemal Baysal; Günay Yetik Anacak; N Ülkü Karabay Yavaşoğlu
Journal:  Cytotechnology       Date:  2018-08-19       Impact factor: 2.058

3.  E7080 (lenvatinib), a multi-targeted tyrosine kinase inhibitor, demonstrates antitumor activities against colorectal cancer xenografts.

Authors:  Armin Wiegering; Doreen Korb; Andreas Thalheimer; Ulrike Kämmerer; Jan Allmanritter; Niels Matthes; Michael Linnebacher; Nicolas Schlegel; Ingo Klein; Süleyman Ergün; Christoph-Thomas Germer; Christoph Otto
Journal:  Neoplasia       Date:  2014-11-20       Impact factor: 5.715

4.  Dystrophin Deficiency Leads to Genomic Instability in Human Pluripotent Stem Cells via NO Synthase-Induced Oxidative Stress.

Authors:  Sarka Jelinkova; Petr Fojtik; Aneta Kohutova; Aleksandra Vilotic; Lenka Marková; Martin Pesl; Tereza Jurakova; Miriama Kruta; Jan Vrbsky; Renata Gaillyova; Iveta Valášková; Ivan Frák; Alain Lacampagne; Giancarlo Forte; Petr Dvorak; Albano C Meli; Vladimir Rotrekl
Journal:  Cells       Date:  2019-01-15       Impact factor: 6.600

5.  CRYAB predicts clinical prognosis and is associated with immunocyte infiltration in colorectal cancer.

Authors:  Junsheng Deng; Xiaoli Chen; Ting Zhan; Mengge Chen; Xisheng Yan; Xiaodong Huang
Journal:  PeerJ       Date:  2021-12-10       Impact factor: 2.984

6.  Ferulic Acid Prevents Angiogenesis Through Cyclooxygenase-2 and Vascular Endothelial Growth Factor in the Chick Embryo Chorioallantoic Membrane Model.

Authors:  Juni Ekowati; Iwan Sahrial Hamid; Nuzul Wahyuning Diyah; Siswandono Siswandono
Journal:  Turk J Pharm Sci       Date:  2020-08-28

Review 7.  Arginine Metabolism and Its Potential in Treatment of Colorectal Cancer.

Authors:  Tao Du; Junyi Han
Journal:  Front Cell Dev Biol       Date:  2021-05-20
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.